AN2 Therapeutics (ANTX) Fundamental Analysis: Revenue, Earnings & Valuation

8.79 / 10

Outperform

Fundamentally, ANTX scores 8.8/10, driven by excellent interest coverage and favorable Revenue‑MV. However, a high long‑term debt‑to‑working‑capital ratio and weak PB‑ROE pose risks. Overall, the fundamentals are rated Outperform.

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score3/3

Weight41.90%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.58%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-4.78%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value98.09

Score0/3

Weight-17.70%

1M Return-4.96%

PB-ROE

Value-0.51

Score1/3

Weight33.86%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.00

Score0/3

Weight-18.20%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.86%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.23%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-4.59%

1M Return-1.13%

Asset-MV

Value-0.55

Score3/3

Weight73.56%

1M Return11.61%

Is ANTX fundamentally strong?

ANTX scores 8.79/10 on fundamentals and holds a Discounted valuation at present. Backed by its -52.14% ROE, 0.00% net margin, -3.48 P/E ratio, 2.30 P/B ratio, and 32.56% earnings growth, these metrics solidify its Outperform investment rating.